Azole-resistant thrush has emerged as a problem in people who are infected with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS), especially those who have low CD4 cell counts who have had a previous relapse of oral candidiasis, and in those who require long-term suppressive antifungal therapy. Because of the development of a standardized methodology for antifungal susceptibility testing and interpretive criteria for resistance testing, studies of the clinical predictive value of in vitro results are possible. In this study, 61% of organisms isolated from patients who were receiving azole therapy and who had clinically resistant thrush had minimal inhibitory concentration values that would classify the isolate as "resistant" or "susceptible dose dependent." In contrast, 86% of isolates from patients with thrush that was clinically responsive to an azole were classified in vitro as "susceptible" or "susceptible dose dependent." No resistant isolates were detected in samples obtained from asymptomatic control patients who were not exposed to azole drugs. Serum levels of azole and CD4 cell counts were also important parameters with regard to prediction of response. We conclude that in vivo and in vitro correlations compare favorably to studies of susceptibility testing in bacteria.
could be successfully treated with higher doses of antifungal agents [13] . As in bacterial susceptibility testing [14] , the clinical interpretation of in vitro data must consider factors that affect the ability to achieve an adequate concentration of the drug at the target site in the patient (e.g., drug dose, absorption, drug interactions, and compliance) and must balance these factors against an impaired immune status of the host or virulence factors of the organism.
In this study, we determined the ability of in vitro susceptibility testing to predict the clinical outcome of oropharyngeal candidiasis in adults and children/adolescents who were infected with HIV.
PATIENTS AND METHODS

Patients.
Patients were selected from among those who were attending the Toronto Hospital Immunodeficiency Clinic and the HIV Clinic at The Hospital for Sick Children (Toronto, Canada) from April 1995 through February 1998. Protease inhibitor therapy became widely available in Canada in July 1996. The diagnosis of oral candidiasis was determined clinically. Pseudomembranous candidiasis was characterized by the observation of typical whitish-yellow, curdlike, easily removable plaques or pseudomembranous lesions on the oropharyngeal mucosa or tongue. Erythematous candidiasis presented as red lesions on the tongue or dorsal palate. No patient with isolated angular cheilitis was included in the study.
Three groups of patients were defined before study entry. Patients with "clinically resistant" thrush had visibly apparent oropharyngeal lesions despite having received 2 weeks of azole therapy (ketoconazole, 1200 mg per day for adults and 5-10 mg per day per kg of body weight for children/adolescents; fluconazole, 1100 mg per day for adults and 3-6 mg per day per kg of body weight for children/adolescents; and itraconazole, 1200 mg twice per day for adults and 2-5 mg per day per kg of body weight for children/adolescents). Patients who had "clinically responsive" thrush included patients who did not have clinically apparent thrush but who had been undergoing chronic suppressive treatment for thrush with orally administered azole drugs at least 3 times per week for the previous 3 months. The group of asymptomatic control patients included patients who had not received azole therapy within the preceding 3 months and who did not have clinically apparent thrush. Adult patients were treated with the capsule or tablet formulation only. Young children received the liquid formulation when they were unable to swallow pills. No patient received other topical antifungal agents (e.g., nystatin) during the study period, although some patients may have received them previously.
At the time of study entry, an oral swab specimen was obtained for culture and susceptibility testing and data were collected regarding patient demographics, CD4 cell count, and use of antiretroviral agents and other medications, including the history of use of antifungal agents during the 3 months prior to the study.
Laboratory evaluations. Oropharyngeal swab specimens were placed into Amie transport medium. Gram stains were performed, and the swabs were inoculated onto Inhibitory Mold Agar (BBL) with ciprofloxacin, 5 mg/mL, and were incubated at 35ЊC for 5 days. Germ tube-positive isolates were identified as Candida albicans, whereas germ tube-negative isolates were examined morphologically on cornmeal Tween 80 agar and were tested by use of API20C (BioMerieux). Isolates not identified to a high confidence level were referred to the Toronto Public Health Laboratory. Candida dubliniensis was distinguished from C. albicans sensu stricto by poor or no growth at 42ЊC and no growth at 45ЊC within 72 h on Sabouraud peptone-glucose agar [15, 16] .
Antifungal susceptibility testing. The susceptibility of each strain to fluconazole, ketoconazole, and itraconazole was determined by use of the broth microdilution method, according to the guidelines of the National Committee for Clinical Laboratory Standards (NCCLS) [12] . End points were read visually. Itraconazole breakpoints were used for ketoconazole on the basis of the similarity of the pharmacokinetics of the 2 drugs and the results of previous pilot data (unpublished data). Lower breakpoints for ketoconazole have been suggested by others [17] .
Serum levels of azole. To test for serum levels of azole, random serum samples were collected from adult patients who were receiving treatment with either fluconazole or ketoconazole at the time of study entry and were stored at Ϫ70ЊC. The time of administration of the last dose of either drug was recorded.
Ketoconazole assay. Ketoconazole concentrations in serum were measured by use of high-performance liquid chromatography with ultraviolet detection after protein precipitation with methanol. A mobile phase that consisted of 40 parts of acetonitrile and 60 parts of 0.05-M potassium phosphate was pumped (model 510, Waters Scientific) at a rate of 2.0 mL/ min through a C18, 5-mm, reverse-phase 4.6-mm ϫ 250-mm column (Beckman Ultrasphere). The column effluent was monitored by use of a variable-wavelength ultraviolet detector (Hewlett-Packard model 1050) at 207 nm. The lower limit of sensitivity of the assay was 0.02 mg/L, with an intraday relative error (percentage coefficient of variation) of !12% and an interday relative error of !9%.
Fluconazole assay. The chromatographic conditions included a mobile phase of 30% methanol and 70% 0.01-M ammonium acetate (pH adjusted to 5). The solvent was pumped through a Beckman Ultrasphere C-18 analytical reverse-phase column and a 1.5-cm Aquapore reverse phase-18 octadecylsilane guard column (Applied Biosystems) at 1.0 mL/min with a pump (Spectra Physics model P100). Ultraviolet absorbance was monitored at 210 nm by use of a Kratos variable wavelength detector. The minimum level of quantification was 100 ng/mL. Standard curves were linear up to 50,000 ng/mL, with deviations for quality control samples and standards of !10%. Error on duplicate analysis was also !10%.
Statistical analysis. Parametric variables were compared by use of the Student's paired t test, and nonparametic variables were compared by use of a 1-way analysis of variance and the Kruskal-Wallis test. Statistical significance was determined by use of SAS, version 6.12 for Windows (SAS Institute).
RESULTS
Patients.
One hundred eighty-nine HIV-infected patients (162 adults and 27 children/adolescents) were enrolled in the study. The patient demographics are outlined in table 1. The adult patients were predominantly men, and the mean patient age was 39.1 years, which is characteristic of the clinic population. The patients with clinically resistant thrush had more advanced HIV infection, which was reflected by the patients' [18] . At the time of enrollment, 26%, 15%, 15%, and 44% of children/adolescents in the cohort were classified as belonging to group N, A, B, or C, respectively. No pediatric/adolescent patient was receiving a protease inhibitor therapy regimen at the time of entry into the study. All patients with clinically resistant thrush had the pseudomembranous form of the disease.
Organisms. The results of oropharyngeal cultures were positive in 90 (48%) of 189 patients, including 21 (87.5%) of 24 patients who had clinically resistant thrush, 19 (33%) of 58 who received suppressive therapy but who didn't have clinical disease, and 50 (47%) of 107 asymptomatic control patients. Patients with clinically resistant thrush were statistically more likely to have positive culture results than were patients in the other groups ( ); however, the frequency of yeast isolation was P ! .001 not different in a comparison of patients with clinically responsive thrush and control patients ( ). Three patients with P p .11 clinically refractory disease provided samples that failed to yield yeast on culture, which may have resulted from a misdiagnosis (thrush can be confused clinically with oral hairy leukoplakia) or a sampling error. The percentage of adult patients with asymptomatic colonization was similar for those who did (13 In vitro susceptibility results. Table 2 lists the MIC 50 /MIC 90 data for isolates categorized according to patient disease classification and current exposure to azole for those who were treated with fluconazole or ketoconazole. The MIC 50 /MIC 90 was lowest for Candida species that were isolated from asymptomatic control patients who had not been exposed to azoles, intermediate in patients without clinical disease who had been undergoing chronic suppressive therapy, and highest for patients with clinically resistant disease. The single isolate from a patient who had clinically resistant thrush and who was receiving itraconazole therapy had an in vitro MIC of 0.03 mg/L (susceptible), whereas the 4 isolates from patients who were receiving long-term suppressive therapy with itraconazole and who did not have thrush had a MIC 50 /MIC 90 of 0.25/0.25 mg/ L (SDD). Figure 1 shows the correlation between response to azole therapy and the in vitro susceptibility category [12, 13] . The data regarding patients who received itraconazole are not included. When the data for all 3 azoles are considered together, 14 (61%) of all 23 isolates from patients with clinically resistant thrush were classified as resistant or SDD in vitro, whereas 19 (86%) of all 22 isolates from patients with clinically responsive thrush were classified as susceptible or SDD.
Of the 12 strains with in vitro resistance to fluconazole (MIC у64 mg/L), 7 (58%) were resistant (MIC у1 mg/L) and 3 (25%) were in the SDD range (MIC, .24-.5 mg/L) for itraconazole, and 8 (67%) were resistant (MIC у1 mg/L) and 3 (25%) were in the SDD range (MIC, .24-.5 mg/L) for ketoconazole.
Serum levels of azole. Levels of fluconazole or ketoconazole in serum were determined at random for 28 of 39 adult patients who were receiving fluconazole and 18 of 29 who were treated with ketoconazole. Table 3 compares the serum levels with regard to clinical classification, in vitro MIC, interpretive category, and the patients' CD4 cell count. No organism was isolated from the oropharynx of 22 patients in whom serum levels were assessed; data from these patients are not included in table 3.
DISCUSSION
Since the introduction of HAART, the rate of incidence of both oral or esophageal candidiasis and fluconazole-resistant thrush has decreased, although the rate of asymptomatic colonization in HIV-infected patients has not changed, as observed in this and other studies [19, 20] . We have observed that rates of yeast colonization have decreased, but that yeast colonization has not been eliminated, by use of long-term suppressive azole therapy. This suggests that significant mucosal colonization persists while patients receive therapy, perhaps because of the patients' underlying immunosuppression or because of the persistence of mutants that are resistant to antifungal agents. The use of azoles did not appear to select for species of organisms with known increased intrinsic azole resistance, because either C. albicans or C. dubliniensis was identified in 95% of isolates obtained from patients who were receiving azole therapy and in 90% of isolates obtained from patients who were not receiving azole therapy. The pathogenicity of isolates other than C. albicans or C. dubliniensis is also called into question, because these isolates were never the sole cause of any case of clinically evident thrush. The use of any azole appeared to select for yeast strains with increased MICs not only to the azole received but, also, to other members in the class, as has been observed elsewhere [21] .
This study was designed to determine how accurately the NCCLS breakpoints for in vitro susceptibility testing of yeasts reflected the clinical response to antifungal agents [12, 13] . We identified 24 isolates from patients with clinically resistant thrush. For 16 of the 24 isolates that were associated with clinical failure of fluconazole therapy, the mean MIC 90 decreased within the range reported to be resistant, and the MIC 50 decreased in the SDD range. This clearly demonstrates that MICs greater than those in range of susceptibility correlate with poor clinical outcome.
Collectively, 14 (61%) of 23 organisms from patients with clinically resistant disease were classified as SDD or resistant in vitro. The correlation was strongest for fluconazole. Similarly, 19 (86%) of 22 isolates obtained from patients with clinically responsive disease were classified in vitro as susceptible or SDD. Isolates obtained from the oropharynx of those who were being successfully treated with an azole may not be reflective of the organism that originally caused the clinical disease, which may have had a lower MIC. Despite this bias, the correlations in this study were still good. No resistant isolates were detected among the asymptomatic control patients who were not recently exposed to azoles. Application of the breakpoints for ketoconazole that have been proposed elsewhere [17] would have resulted in 71% of the isolates obtained from patients with clinical resistance to ketoconazole being classified as resistant in vitro. However, 75% of the isolates obtained from patients with clinically responsive disease and 25% of the isolates obtained from control patients also would have been classified as resistant. We believe that the breakpoints that we selected better correlate with clinical outcome.
To fully evaluate the significance of the breakpoints, it is important to determine the levels of drug achieved at the site of the infection relative to the MIC of the organism. We used serum levels of azole as an estimate of levels in the oropharynx. Previous studies found that levels in saliva were similar or higher than corresponding values in serum [22, 23] . It is uncertain whether a peak or a trough level is the most important predictor of outcome. The serum levels of fluconazole that we observed were similar to those reported in other populations [24] , and they similarly demonstrated a wide variability. The mean serum concentration for those who had taken their dose during the 7 h prior to testing (i.e., peak concentration) was 7.55 mg/L (range, 0.58-45.07 mg/L); for those who had taken their dose 17 h prior to testing (i.e., trough concentration), it was 2.86 mg/L (range, 0-8.21 mg/L). For patients with clinically responsive disease in whom no organism had been isolated, the mean peak and trough levels were not different from those than in the other groups (data not shown).
The relationship among clinical, culture, and serum azole data was evaluated in patients for whom all data were available. Resistance in vitro predicted clinical failure in 4 (80%) of 5 fluconazole-treated patients. These 4 patients all had serum levels (2 were peak concentrations and 2 were trough concentrations) that were lower than the MIC for that organism. The SDD designation of 5 isolates predicted clinical resistance in 3 of 5 patients, one of whom had no detectable serum level of fluconazole (this patient had possible compliance problems) and 2 of whom had peak serum levels that were 2-4-fold lower than their respective MICs. Of the 7 susceptible isolates, 5 were clinically resistant, and all patients had serum levels (5 were peak concentrations and 2 were trough concentrations) that were lower than the MIC of the causative organisms and CD4 cell counts !23 cells/mm 3 . Among ketoconazole-treated patients, in vitro resistance predicted the single clinical failure, despite a trough serum level that was 2 times higher than the MIC of the organism. The SDD designation of 1 isolate predicted clinical failure in a patient with a trough serum level that was just marginally greater than the MIC of the isolate and a CD4 cell count of 29 cells/ mm 3 . Of the 7 susceptible isolates, 1 was clinically resistant despite a peak serum level that was much greater than the MIC of the isolate. This patient had a CD4 cell count of 40 cells/ mm 3 . The other 6 isolates were clinically responsive, and 3 of the 6 had serum levels that were greater than the MIC. It would appear that in vitro resistance has a high correlation with clinical resistance independent of other factors. However, a susceptible or SDD designation can be overwhelmed by an inadequate serum level (resulting from inadequate dosing, absorption, or adherence) or possibly by an inadequate immune system, as reflected by a low CD4 cell count.
The isolate obtained from the single patient with clinical failure to respond to itraconazole had an MIC of 0.03 mg/L at presentation. It was interesting to note that, at follow-up, the MIC had increased incrementally, reaching a final level of у64 mg/L. This isolate may have had a resistance mechanism that was not initially detected by means of routine testing but that eventually became detectable as resistant with repeated passage in the host under drug-selection pressure.
The in vivo and in vitro correlations observed in our study compare favorably with those reported in studies of bacterial susceptibility testing [25] [26] [27] . In studies that have involved a variety of patient populations and types of bacterial infections, favorable responses were seen in 60%-100% of patients who were treated with antibiotics to which the organism was susceptible in vitro, compared with 0%-63% of patients who were infected with organisms that were resistant. These studies support the conclusion that antifungal susceptibility testing is at least as good as bacterial susceptibility testing in predicting clinical susceptibility-and probably better in predicting clinical failure of thrush to respond to azole therapy in HIVinfected patients. The failure of a susceptible organism to predict clinical success, especially for fluconazole, appears to be related more to the immune status of the patient and to the drug level in serum than to the in vitro data.
We would not recommend in vitro susceptibility testing for all cases of thrush in people who are living with HIV. However, in selected patients who fail to respond to therapy, a finding of in vitro resistance would suggest that alternative agents should be considered, whereas a finding of SDD would suggest that increasing the dose might be beneficial. A susceptible in vitro result found in a patient with clinically resistant thrush would suggest that factors such as compliance, absorption, and dose should be considered in addition to the degree of the patient's immunosuppression.
In summary, this study demonstrates that the clinical usefulness of in vitro susceptibility testing of yeasts by use of the NCCLS reference method is at least as effective as bacterial susceptibility testing and is especially useful in predicting which patients are not likely to respond to therapy.
